Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — Shareholder Meeting (September 2023)
21 slides from Aarti Pharmalabs's shareholder meeting presentation, Sep 14, 2023
Slide 1: Exchange filing letter: Presentation to Shareholders
September 14, 2023 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE:
Slide 2: Aarti Pharmalabs Limited Annual General Meeting FY 22-23
Aarti Pharmalabs Limited Annual General Meeting FY 22-23 1
Slide 3: Index
Index 1 Company Overview 2 Financial Performance 2
Slide 4: Company Overview
Company Overview ……………………………………………….. 3
Slide 5: Aarti Pharmalabs at a Glance
Aarti Pharmalabs at a Glance Overview FY 23 - Consolidated Revenue Breakup (Rs. Crores) ▪ Established by first generation technocrats in 1984 ▪ Specialized key business verticals ■ API & Intermediates, ■ CDMO & CMO Services ■ Xanthine derivatives & allied 59% ▪ Strong R&D capabilities with IPRs for
Slide 6: Journey
Journey Expanded block •Unit 5 commissioned for CSD, Vapi and for Caffeine Production Oncology API, Tarapur. with a capacity of 100 block at Unit 4 Commissioning of first 1st Clearance of the Oncology block at MT per month audited by Acquired Land at Incorporated API manufacturing Unit USFDA & EUGMP
Slide 7: Manufacturing Facilities
Manufacturing Facilities Unit - II Custom Manufacturing Units Location synthesis division (CSD) Dombivali Unit - I (API & Intermediates) Location: Vapi Unit - II (API Intermediates & R&D Centers Vapi Custom Synthesis Unit) Location: Vapi, Unit – III (Xanthine Unit) Gujara Dombivali Tarapur Unit – IV
Slide 8: Key Business Verticals
Key Business Verticals APIs and Intermediates CDMO / CMO Services Xanthine derivatives & Allied (Caffeine and others) ❏ US FDA approved manufacturing facility ❏ CRAMs activity focused on API & intermediates ❏ Largest Indian Manufacturer for ❏ Exports to lucrative regulated markets - US, EU and Japan
Slide 9: Strong Presence in API & Intermediates
Strong Presence in API & Intermediates 50 10 40 20 ~100 APIs have been New APIs are under US DMF approvals CEP approvals Generic Intermediates commercialized by APL development at APL’s obtained across available for sale in are available at R&D, since it entered the dedicated R&D facility multiple t
Slide 10: Xanthine Derivatives
Xanthine Derivatives • Xanthine derivatives are synthetic End Use Certifications compounds that resemble natural occurring xanthines such as caffeine etc., • Commonly used as mild stimulants & Cola Drinks Energy Drinks bronchodilators, notably in the treatment of asthma or influenza symptoms • 2 ded
Slide 11: R&D Strengths & Capabilities
R&D Strengths & Capabilities 3 70+ 7 13 52 State-of-the-art R&D centres at Maharashtra & Scientists Patents Granted Process patents filed PHDs. Gujarat 150+ 50+ Process for more than 150 Intermediates developed More than 75 API and manufactured on kilo commercialized lab scale 160 39 crs R&D Spend i
Slide 12: Financial Performance
Financial Performance ……………………………………………….. 11
Slide 13: Consolidated Financial Performance
Consolidated Financial Performance ……………………………………………….. 12
Slide 14: FY23: Important Numbers (Consolidated)
FY23 : Important Numbers (Consolidated) Highlights of Q4 FY 24 Revenue from Net worth EBITDA operations INR 1945 crs INR 344 crs INR 1558 crs Net Debt to Equity PAT EPS INR 21.35 0.12 INR 193 crs 13
Slide 15: FY23 Highlights (Consolidated)
FY23 Highlights (Consolidated) Amtount in Rs. Crs. Total Income EBITDA Note: The scheme of Demerger of Pharma business of Aarti Industries Limited into Aarti Pharmalabs Limited was effective from 1-Jul-2021. Hence the figures for FY 2022-23 are not comparable with that 19 of FY 2021-22
Slide 16: FY23 Highlights (Consolidated)
FY23 Highlights (Consolidated) Amtount in Rs. Crs. Profit Before Tax Profit After Tax Note: The scheme of Demerger of Pharma business of Aarti Industries Limited into Aarti Pharmalabs Limited was effective from 1-Jul-2021. Hence the figures for FY 2022-23 are not comparable with that of FY 2021-22 1
Slide 17: Standalone Financial Performance
Standalone Financial Performance ……………………………………………….. 16
Slide 18: FY23 Highlights (Standalone)
FY23 Highlights (Standalone) Total Income EBITDA 1512 310 943 182 21-22 22-23 21-22 22-23 Note: The scheme of Demerger of Pharma business of Aarti Industries Limited into Aarti Pharmalabs Limited was effective from 1-Jul-2021. Hence the figures for FY 2022-23 are not comparable with that of FY 2021-
Slide 19: FY23 Highlights (Standalone)
FY23 Highlights (Standalone) Profit Before Tax Profit After Tax 233 172 134 107 21-22 22-23 21-22 22-23 Note: The scheme of Demerger of Pharma business of Aarti Industries Limited into Aarti Pharmalabs Limited was effective from 1-Jul-2021. Hence the figures for FY 2022-23 are not comparable with th
Slide 20: FY23 Highlights (Standalone) - Ratios
FY23 Highlights (Standalone) - Ratios Particulars 22-23 21-22 Return on Capital Employed 16% 10% Return on Equity 13% 9% Net Debt / Equity 0.13 0.25 Current Ratio 2.11 1.85 Note: The scheme of Demerger of Pharma business of Aarti Industries Limited into Aarti Pharmalabs Limited was effective from 1-
Slide 21: Thank You
THANK YOU Aarti Pharmalabs Limited #204, Udyog Kshetra, 2nd Floor, Mulund Goregaon Link Road, Mulund West, Mumbai - 400080, Maharashtra, India. Email: investorrelations@aartipharmalabs.com Contact: +91 22 67976666 20
Aarti Pharmalabs — Shareholder Meeting (September 2023) on 6ix